Summary Report of Consolidated Financial Results
For the Six Months Period ended September 30, 2015

November 11, 2015
stCompany name: NIPRO CORPORATION
TSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Yoshihiko Sano, President and Representative Director
Contact person: Kimihito Minoura, Director and General Manager of Corporate Planning Headquarters
TEL: (06)6372-2331
Filing date of quarterly reporting: November 13, 2015
Payment date of cash dividends: December 8, 2015
Supplemental material on quarterly reporting: Yes
Presentation on quarterly results: Yes (for institutional investors and analysts)(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Six Months ended September 30, 2015 (From April 1, 2015 to September 30, 2015)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
6 months ended September 30, 2015
179,530
16.2
11,651
46.8
10,140
17.7
5,646
3.2
6 months ended September 30, 2014
154,501
7.7
7,939
36.9
8,618
48.9
5,470 108.8
Note: Comprehensive income 6 months ended September 30, 2015: 2,885 million yen (142.1%)
yen (-%)

6 months ended September 30, 2015
6 months ended September 30, 2014

Earnings per share
Yen
33.29
36.28

(2) Consolidated Financial Position
Total Assets
Millions of yen
6 months ended September 30, 2015
708,921
Year ended March 31, 2015
695,306
Note: Equity

2.

6 months ended September 30, 2014: (209) million

Diluted Earnings per share
Yen
32.34

Net Assets
Millions of yen
178,385
178,8106 months ended September 30, 2015: 167,868 million yen

Equity Ratio
%
23.7
24.1

Year ended March 31, 2015: 167,659 million yen

Dividends

Year ended March 31, 2015
Year ending March 31, 2016
Year ending March 31, 2016
(Forecast)

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
18.00
14.50
17.00

First-quarter
Yen
-

-

Annual Dividends

Yen
32.50

18.00

35.00

Note: Revisions to the forecast of cash dividends in the current quarter: No
3.

Forecast of Consolidated Financial Results for the Year ending March 31, 2016 (From April 1, 2015 to March 31, 2016)(Note: The % displays in the line of year ending March 31, 2016 show increase/decrease ratio against the year ended March 31, 2015)

Operating
IncomeNet Sales
Millions of yen%

Millions of yen

Ordinary Income%

Millions of yen%

365,000 12.3
25,00050.9
19,300(1.8)
Note: Revisions to the forecast of consolidated financial results in the current quarter: Yes
Year ending March 31, 2016

Net Income
Millions of yen

16,700%33.9

Earnings
per Share
Yen
98.47

*Notes(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0Removal: 0(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No[3] Change in accounting estimate: No[4] Restatement: No

Note: More information can be found in P.5 “2. Summary (Other) Information, (3) Changes in Accounting Policies andAccounting Estimate and Restatement” in the attachment.
(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
6 months ended September 30, 2015: 171,459,479 sharesYear ended March 31, 2015: 171,459,479 shares[2] Number of treasury stock at end of the period:
6 months ended September 30, 2015:

1,791,299 sharesYear ended March 31, 2015:

1,899,861 shares[3] Average number of shares during the period:
6 months ended September 30, 2015: 169,602,699 shares

6 months ended September 30, 2014: 150,792,006 shares

Note: Number of the treasury stocks as of September 30, 2015 included 843,900 shares, and as of March 31, 2015
included 953,100 shares owned by Trust and Custody Service Bank, Ltd (Trust Account E).

*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.
*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.4“1. Qualitative Information for the Six-Month Period Ended September 30, 2015, (3) Commentary on
Forward-Looking Statements Including Forecast of Consolidated Financial Results” in the attachment.

Table of Contents
1.

2.

3.

Qualitative Information for the Six-Months Period ended September 30, 20152(1) Commentary on Business Results

2(2) Analysis Concerning Financial Position

4(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results

4

Summary (Other) Information

5(1) Changes in Significant Consolidated Subsidiaries

5(2) Accounting Treatments Simplified or Unique for Preparation

5(3) Changes in Accounting Policies and Accounting Estimate and Restatement

5

Consolidated Financial Statements

6(1) Quarterly Consolidated Balance Sheets

6(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income8(3) Quarterly Consolidated Statements of Cash Flows

9(4) Notes Regarding Consolidated Financial Statement

11(Notes regarding going concern)

11(Notes regarding significant changes in the amount of shareholders’ equity)

11(Segment Information)

11

-1-

1. Qualitative Information for the Six-Month Period Ended September 30, 2015
(1) Commentary on Business Results
During the six months of the fiscal year under review, the economic slowdown in China triggered the economic
deterioration in developing countries while developed countries such as the United States remained on a recovery trend.
The Japanese economy also remained on a recovery trend despite the uncertainty about the economic outlook such asconcerns about the Chinese economy.
Under such circumstances, the Nipro Group has worked to improve operating results through its continued efforts to
expand sales and reduce costs.
As a result, consolidated sales for the six-month period ended September 30, 2015 increased by 16.2% from the same
period of the previous year to 179,530 million yen. As for the profit, consolidated operating income increased by 46.8%
from the same period of the previous year to 11,651 million yen. Consolidated ordinary income increased by 17.7% fromthe same period of the previous year to 10,140 million yen. Consolidated net income attributable to owners of parent
increased by 3.2% from the same period of the previous year to 5,646 million yen due to the decrease in income
taxes-current.
The overview of the results for the current quarter period under review by business segment is as follows.

(i)

Medical-Related BusinessLooking at the domestic market of Medical-Related Business, sales of cardiac surgery (CVS) products were below

expectations while injection-transfusion products, enteral-alimentation products, testing products, dialysis products, andcardiovascular products performed solidly. Especially in the field of dialysis products, sales of HDF filter and dialysis
monitoring devices largely increased. On the other hand, for the Pharmaceutical Sales Division, the sales were steadydue to the expansion of the market with the promotion policy of generic drugs, the expansion of existing products and thelaunch of addenda listing items in June though the competitive environment of domestic market became fiercer by theappearance of manufactures of original drugs running sideline business. In addition, large markets of new big listing
items have being continuously entered by over 30 competitors and initial sales of AG (authorized generic) allows tomarket occupation, that made the market price competition more intensified to impact significantly to sales and profit.
However, we have strengthened the sales promotion to dispensing pharmacies, diagnosis procedure combination (DPC)hospitals and prescribers. Also we tried to increase the share of orally administered drugs and external preparations andworked harder for information offering activities of injectables based on the collaboration with pharmaceutical wholesaler.
Meanwhile, overseas sales increased significantly from the same period of the previous year as we strengthened thesales of dialysis products and hospital products. However, the profits decreased with the exchange losses caused by the
impact of foreign exchange markets.
We strengthened the overseas sales organization and stepped up our direct sales activities with the aim of quickly
responding further to front-line needs and boosting overseas sales. Particularly in India, we relocated headquarter ofsales company to Hyderabad to strengthen the sales activities. We will open sales offices in major cities sequentially. In
addition, new overseas manufacturing facilities (in India, Indonesia, Bangladesh and Hefei in China) further improved
their production system and realized production expansion under established quality system to promote their sales widelyin their countries and surrounding areas. Especially production of dialyzers in India and Hefei plants has increasedsmoothly to contribute the sales increase and syringe from Indonesia plants has supported the sales growth as well.
As a result, net sales of this business increased by 17.8% from the same period of the previous year to 132,547 million
yen.

(ii)

Pharmaceutical-Related BusinessIn the Pharmaceutical-Related Business, we have broadened our contracted manufacturing operation to encompass
contracts to develop products from the formulation design of orally administered drugs and external preparations and todevelop products using our expertise developing and supplying vials, syringes, bags, and other packaging containers. We-2-also endeavored to expand the contracted business by offering a diverse range of detailed yet wide-ranging contract
services, such as support for lifecycle management where we believe we can enhance the value-added features andrealize distinct service differentiation. In addition, efforts to upgrade and expand our contracted manufacturing capabilities
for the dedicated biopharmaceuticals line and the oral drugs and injectable solutions lines at the high potency active
pharmaceutical ingredients manufacturing plant contributed to strong sales of contracted manufacturing.
Sales of pharmaceutical containers as well as devices related to pharmaceutical preparation and administration steadily
increased due to offering containers and systems suitable to each pharmaceutical product developed by ourselves or
through joint development with pharmaceutical manufactures. Such efforts were made to meet various needs in the
medical front, including small-volume bags, materials for pre-filled syringes (plastic and glass), etc., on top of rubber
stoppers for pharmaceutical and vaccine use and containers for kit products. In addition, under the government’s policy to
curb medical expenses, we have worked together with domestic and foreign pharmaceutical manufactures in enhancing
comprehensive lifecycle management of pharmaceutical products, taking into consideration the development of
combination products (our original collaboration between pharmaceutical products and medical devices), self-injection
systems, and dosage form/administrating path modification in the future.
As a result, net sales of this business increased 9.4% from the same period of the previous year to 30,393 million yen.

(iii) Glass-Related BusinessIn the Glass-Related Business, adding to our conventional products, we have made effort of academic and sales
activities to meet global customer needs and acquire new demands while we have promoted the development of newtechnologies and new products domestically and internationally to support injectable formulation and filling process withhigh stability.
For the pharmaceutical packaging in domestic glass department, we increased the sales mainly in tube glass, vials andprefilled syringe. As for “Biwako Factory,” a state-of-the-art plant for pharmaceutical packaging, with the purpose of further
improving our quality assurance system for good manufacturing practice (GMP), the factory aims to establish the
production and sales system of high quality glass for medical purpose and promotes their activities to meet the needsfrom global customers.
Regarding overseas glass department, we have expanded the sales of high-valued products such as syringe andvarious vials which demand is increasing in the mature markets such as Europe and the United States and also
strengthened the sales of tube glass, ampoules and vials in the emerging markets including China, India and Russia. Dueto these activities, the sales increased and the profitability was improved in the markets respectively. Especially in China,
the largest market of emerging countries, the market has greatly changed to require higher-quality medical containers
than conventional products following the order of government. Under these circumstances, we have invested inequipment to introduce high-quality products and established a company in Shanghai to supervise the three existing
plants in China. The progress toward to entre high quality market has been accelerated.
In this business, we have promoted the changing to general pharma packaging business with a fusion of products andtechnologies cultivated in both medical and pharmaceutical related businesses such as rubber stopper and plastic
containers as well as glass containers. In addition, the standardization of product specifications and services in each
office has been also promoted to meet the requirement from global pharmaceutical companies. We will promote effective
investment domestically and internationally to strengthen production capacity of conventional products, improve thequality and introduce new products for the continuous expansion of our business providing the products and services witha user-focused approach.
Among other glass-related products, overseas demands of glass for thermos bottles decreased but whole sales of thisdepartment remained solidly.
As a result, net sales of this business increased 17.3% from the same period of the previous year to 16,573 million yen.

-3-

(iv) Other BusinessAmong other business, sales from the real-estate rental business were 16 million yen (down by 74.5% from the same
period of the previous year).
(2) Analysis Concerning Financial Position[1] Analysis Concerning the Conditions of Assets, Liabilities and Net Assets
Total assets increased by 13,614 million yen from the end of the previous year to 708,921 million yen. Current assets
increased by 1,545 million yen primarily due to an increase of 4,830 million yen in other current assets, and noncurrent
assets increased by 12,069 million yen primarily due to an increase of 10,538 million yen in other of investment and otherassets.
Total liabilities increased by 14,039 million yen from the end of the previous year to 530,536 million yen. Current
liabilities increased by 23,484 million yen primarily due to an increase of 20,742 million yen in short-term loans payable,
and noncurrent liabilities decreased by 9,444 million yen primarily due to a decrease of 8,294 million yen in long-termloans payable.
Total net assets decreased by 425 million yen from the end of the previous year to 178,385 million yen. Shareholders’equity increased by 2,469 million yen and accumulated other comprehensive income decreased by 2,260 million yen.
[2] Condition of cash flow
The ending balance of cash and cash equivalents in the period under review decreased 7,822 million yen from theprevious year to 90,376 million yen.
(Cash flows from operating activities)
Net cash provided by operating activities was 937 million yen. The main accounts of cash inflow were income before
income taxes, 9,248 million yen and depreciation and amortization, 14,381 million yen. The main account of cash
outflow was decrease (increase) in other assets, 8,000 million yen.
(Cash flows from investing activities)
Net cash used in investing activities was 27,452 million yen. The main account of cash inflow was proceeds fromwithdrawal of time deposits, 6,479 million yen. The main accounts of cash outflow were purchase of noncurrent assets,
18,895 million yen.
(Cash flows from financing activities)
Net cash provided by financing activities was 9,035 million yen. The main account of cash inflow was proceeds fromlong-term loans payable, 37,035 million yen. The main account of cash outflow was repayment of long-term loans payable,
25,270 million yen.

(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results
The Company expects that the global economy will continue to stay on a moderate recovery trend despite the increasing
uncertainty about the future outlook caused by economic slowdown in China and the Japanese economy will also remain on
a recovery trend while it will be affected by the global trend.
Even under such circumstances, the Nipro Group will work to improve profits through its continued efforts to expand
sales and reduce production costs.
We have revised the forecast of consolidated financial results for the year ending March 31, 2016, which wasannounced on August 11, 2015, based on the current movement in performance.

-4-2. Summary (Other) Information(1) Changes in Significant Consolidated Subsidiaries
N/A(2) Accounting Treatments Simplified or Unique for Preparation
N/A(3) Changes in Accounting Policies and Accounting Estimate and Restatement(Change in Accounting Policies)
Application of the Accounting Standard for Business Combinations and related accounting standards
The Company has applied the “Accounting Standard for Business Combinations” (ASBJ Statement No. 21, September
13, 2013; hereinafter the “Accounting Standard for Business Combinations”), “Accounting Standard for Consolidated
Financial Statements” (ASBJ Statement No. 22, September 13, 2013; hereinafter the “Accounting Standard forConsolidated Financial Statements”), and “Accounting Standard for Business Divestitures” (ASBJ Statement No. 7,
September 13, 2013; hereinafter the “Accounting Standard for Business Divestitures”), etc., effective from the first quarter
under review. As a result, the method of recording the amount of difference caused by changes in the Company’sownership interests in subsidiaries in the case of subsidiaries under ongoing control of the Company was changed to one
in which it is recorded as capital surplus, and the method of recording acquisition-related costs was changed to one inwhich they are recognized as expenses for the fiscal year in which they are incurred.
Furthermore, for business combinations carried out on or after the beginning of the first quarter under review, theaccounting method was changed to one in which the reviewed acquisition cost allocation resulting from the finalization of
the tentative accounting treatment is reflected in the quarterly consolidated financial statements for the quarterly period inwhich the business combination occurs.
In addition, a change in the presentation of quarterly net income, etc. and a change in the presentation of the minority
interests to non-controlling interests were adopted. In order to reflect these changes in presentation, the quarterly
consolidated financial statements for the first quarter of the previous fiscal year and the consolidated financial statements
for the previous fiscal year were reclassified.
For the quarterly consolidated cash flow, cash flow related to acquisition or sales of shares of a subsidiary within thescope of changes are classified into net cash provided by investing activities, and cash flow related to purchase cost ofshares of subsidiaries resulting in change in scope of consolidation or purchases or sales cost of shares of subsidiary
within the scope of changes are classified into net cash provided by operating activities.
The application of the Accounting Standard for Business Combinations and related accounting standards is subject tothe transitional treatment provided for in Paragraph 58-2 (4) of the Accounting Standard for Business Combinations,Paragraph 44-5 (4) of the Accounting Standard for Consolidated Financial Statements, and Paragraph 57-4 (4) of the
Accounting Standard for Business Divestitures. Accordingly, these standards have been applied prospectively from the
beginning of the first quarter under review.
As a result, capital surplus decreased 635 million yen and retained earnings decreased 148 million in the current
quarterly period under review. In addition, consolidated operating income, consolidated ordinary income and consolidated
income before income taxes increased 18 million yen, respectively.

-5-3. Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets](Millions of yen)
As ofMarch 31, 2015
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Net defined benefit asset
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-6-

As of
September 30, 2015

112,871
114,477
67,412
12,14922,913
6,963
16,341(2,783)350,346

104,861
112,269
69,09012,68426,016
6,702
21,172(907)
351,891

174,138(81,157)
92,980212,911(150,454)
62,45722,027
3,058(1,957)
1,100
31,242
42,619(32,232)
10,387220,195

178,345(84,157)
94,188222,434(155,883)
66,55021,8762,944(1,992)952
32,25944,935(33,594)
11,340227,167

26,364
1,625
16,37944,36925,637
2,638
15,642
43,91864,076140
7,899
11,901(3,622)80,395344,960
695,306

61,656453
7,359
22,439(5,966)85,942357,029
708,921

(Millions of yen)
As ofMarch 31, 2013
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Notes payable - facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Long-term loans payable
Lease obligations
Deferred tax liabilities
Net defined benefit liability
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

-7-

As of
September 30, 2015

51,750136,359
10,00027,840828
11,679
436
3,934
3,621
123
2,641
29,184278,401

55,985
157,1021,000
28,465
1,108
7,969
－
5,540
5,011
267
5,768
24,667
301,885

20,592
205,621
3,127
2,162
3,841
524
11
2,214
238,095
516,496

18,910
197,326
3,733
1,809
4,075
530
10
2,255
228,651
530,536

84,397635
58,885(1,686)142,231

84,397－
61,891(1,588)144,701(2,311)39
27,870(170)
25,427
11,150178,810695,306(2,294)35
25,548(122)
23,166
10,561
178,385
708,921

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]Quarterly Consolidated Statements of Income(Amount: million yen)
FY2014 first six months(From April 1, 2015
to September 30, 2015)
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Foreign exchange gain
Reversal of allowance for doubtful accounts
Other
Total non-operating income
Non-operating expenses
Interest expenses
Equity in losses of affiliates
Foreign exchange losses
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Gain on sales of investment securities
Compensation income
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Loss on valuation of investment securities
Loss on sales of investment securities
Reversal of allowance for doubtful accounts
Other
Total extraordinary losses
Income before income taxes
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interests
Net income attributable to owners of parent

FY2015 first six months(From April 1, 2015
to September 30, 2015)

154,501
107,832
46,66838,728
7,939

179,530
123,116
56,41344,762
11,651

362
829
1,940
－
1,012
4,144

410
753
－
363
663
2,191

2,027
80
－
1,356
3,465
8,618

2,119
95
364
1,122
3,702
10,140

27
3,402
33
20
3,483

270
－
120
50
441

38
0
1,233
－
33
1,305
10,796
4,119
1,032
5,152
5,644
174
5,470

48
80
289
824
90
1,333
9,248
4,814
(1,302)
3,511
5,736
90
5,646

[Qarterly Consolidated Statements of Comprehensive Income](Amount: million yen)
FY2014 first six months(From April 1, 2015
to September 30, 2015)
Income before minority interests
Other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Share of other comprehensive income ofentities accounted for using equity method
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to owners of the parent
Comprehensive income attributable to minority interests-8-

FY2015 first six months(From April 1, 2015
to September 30, 2015)

5,644

5,736

(654)
(84)
(5,166)50

17(3)(2,266)48－

13(5,854)
(209)
(18)
(190)

(2,191)
3,545
3,385
160

(3) [ Quarterly Consolidated Statements of Cash Flows]

FY2014 first six months(From April 1, 2014
to September 30, 2014)
Net cash provided by (used in) operating activities
Income before income taxes
Depreciation and amortization
Impairment loss
Amortization of goodwill
Share of (profit) loss of entities accounted for using equity method
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in ｎet defined benefit liability
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Loss (gain) on sales of investment securities
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Decrease (increase) in other assets
Increase (decrease) in other liabilities
Other loss (gain)
SubtotalInterest and dividends income received
Interest expenses paid
Other proceeds
Other payments
Income taxes paid
Net cash provided by (use in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of investment securities
Proceeds from sales of investment securities
Payments for sales of investments
in subsidiaries resulting in change in scope of consolidation
Purchase of noncurrent assets
Proceeds from sales of noncurrent assets
Payments for retirement of noncurrent assets
Net decrease (increase) in short-term loans receivable
Payments of loans receivableCollection of loans receivable
Other payments
Other proceeds
Net cash provided by (use in) investment activities-9-(Amount: million yen)
FY2015 first six months(From April 1, 2015
to September 30, 2015)

10,796
12,835
12
2,598
80
102
114
(1,191)
2,027(697)(2,169)(3,004)(3,954)
3,110(3,456)(3,684)(254)
13,2671,131(2,048)140(145)(9,868)
2,476

9,248
14,381
0
2,084
95
377
352
(1,164)
2,119
(877)
289
(1,699)(2,680)
4,045(8,000)(6,385)(111)
12,072
1,163(2,128)169(210)(1,760)9,307(8,706)
7,788(1,484)6,227(6,094)
6,479
(200)
617

(751)

－

(18,371)
2,094
(9)
(14)
(146)
82
－
16
(13,275)(18,895)437(13)(2,530)(1,625)
1,607(7,270)36(27,452)

(Amount: million yen)
FY2015 first six months(From April 1, 2015
to September 30, 2015)

FY2014 first six months(From April 1, 2014
to September 30, 2014)
Net cash provided by (use in) financial activities
Net increase (decrease) in short-term loans payable
Proceeds from long-term loans payable
Repayment of long-term loans payable
Redemption of bonds
Proceeds from sales of treasury shares
Proceeds from sales and leasebacks
Repayments of finance lease obligations
Cash dividends paid
Cash dividends paid to minority shareholders
Payments from changes in ownership interests in subsidiaries
that do not result in change in scope of consolidation
Other payments
Net cash provided by (use in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of paid
Increase in cash and cash equivalentsfrom newly consolidated subsidiary
Cash and cash equivalents at end of period- 10 -

3,962
55,539(28,155)(3,867)108－(634)(2,204)(20)

1,082
37,035(25,270)(1,057)
99
1,317
(566)
(2,468)(22)－(1,113)(0)24,727(103)
13,82470,892

(0)
9,035
513
(8,596)98,199655

773

85,37290,376

(3) Notes Regarding Consolidated Financial Statement(Notes regarding going concern)
N/A(Notes regarding significant changes in the amount of shareholders’ equity)
Effective from the first quarter under review, the Company has applied the “Accounting Standard for Business
Combinations and related accounting standards”. Please refer to “Change in Accounting Policies” about the impact of
this change.
(Segment Information)Ⅰ

FY2014 (From April 1, 2014 to September 30, 2014)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

112,538

27,775

14,124

154,437

63

154,501－

154,501(2)Inter-segment sales
and transfers

788

4,100

322

5,211

17

5,229

(5,229)－Total

113,326

31,875

14,447

156,64980

159,730(5,229)154,501

Segment profit

11,1544,860(1,603)

14,41176

14,488(6,548)

7,939(Notes)
1.
2.
3.
2.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (6,548) million yen includes elimination of inter-segment transaction of(1,232) million yen and corporate cost of (5,316) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment
N/A- 11 -

Ⅱ

FY2014 (From April 1, 2015 to September 30, 2015)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Consolidated
Statements ofIncome(Note.3)

Adjustment(Note.2)

Net sales(1)Sales to third parties

132,547

30,393

16,573

179,514

16

179,530-

179,530(2)Inter-segment sales
and transfers

972

4,205

451

5,629

17

5,647

(5,647)-

Total

133,520

34,59817,024

185,144

34

185,178(5,647)

179,530

Segment profit

14,446

5,449

(997)

18,89833

18,932(7,280)11,651(Notes)1.
2.
3.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (7,280) million yen includes elimination of inter-segment transaction of (604)million yen and corporate cost of (6,676) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Changes in Reportable Segments
Effective from the first quarter under review, the method of recording the amount of difference caused by changes in
the Company’s ownership interests in subsidiaries in the case of subsidiaries under ongoing control of the Company
was changed to one in which it is recorded as capital surplus, and the method of recording acquisition-related costs waschanged to one in which they are recognized as expenses for the fiscal year in which they are incurred.
As a result, the amount of segment profit in Glass-Related business in the current quarter under review increased 18
million yen compared to the conventional method.
3. Information on Impairment Loss on Fixed Assets and on Goodwill by Reportable Segment
N/A- 12 -